Compare CFFN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | GOSS |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.8M | 726.8M |
| IPO Year | 1999 | 2019 |
| Metric | CFFN | GOSS |
|---|---|---|
| Price | $6.99 | $3.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.75 | ★ $8.60 |
| AVG Volume (30 Days) | 787.6K | ★ 3.0M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $200,291,000.00 | $44,051,000.00 |
| Revenue This Year | $16.44 | N/A |
| Revenue Next Year | $3.40 | $6.41 |
| P/E Ratio | $13.46 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $4.90 | $0.76 |
| 52 Week High | $7.08 | $3.80 |
| Indicator | CFFN | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 70.11 | 69.66 |
| Support Level | $6.67 | $3.34 |
| Resistance Level | $7.08 | $3.80 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 90.00 | 83.64 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.